Journal of Clinical Oncology, Vol 19, Issue 3
(February), 2001: 666-675
© 2001 American Society for Clinical Oncology
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
By John P. Stein,
Gary Lieskovsky,
Richard Cote,
Susan Groshen,
An-Chen Feng,
Stuart Boyd,
Eila Skinner,
Bernard Bochner,
Duriayai Thangathurai,
Maged Mikhail,
Derek Raghavan,
Donald G. Skinner
From the Departments of Urology, Medicine, Pathology, and Preventive Medicine, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA.
Address reprint requests to John P. Stein, MD, University of Southern California, Norris Comprehensive Cancer Center, MS no. 74, Department of Urology, 1441 Eastlake Ave, Suite 7416, Los Angeles, CA 90089; email: stein{at}hsc.usc.edu
PURPOSE: To evaluate our long-term experience with patients treated uniformly with radical cystectomy and pelvic lymph node dissection for invasive bladder cancer and to describe the association of the primary bladder tumor stage and regional lymph node status with clinical outcomes.
PATIENTS AND METHODS: All patients undergoing radical cystectomy with bilateral pelvic iliac lymphadenectomy, with the intent to cure, for transitional-cell carcinoma of the bladder between July 1971 and December 1997, with or without adjuvant radiation or chemotherapy, were evaluated. The clinical course, pathologic characteristics, and long-term clinical outcomes were evaluated in this group of patients.
RESULTS: A total of 1,054 patients (843 men [80%] and 211 women) with a median age of 66 years (range, 22 to 93 years) were uniformly treated. Median follow-up was 10.2 years (range, 0 to 28 years). There were 27 (2.5%) perioperative deaths, with a total of 292 (28%) early complications. Overall recurrence-free survival at 5 and 10 years for the entire cohort was 68% and 66%, respectively. The 5- and 10-year recurrence-free survival for patients with organ-confined, lymph node–negative tumors was 92% and 86% for P0 disease, 91% and 89% for Pis, 79% and 74% for Pa, and 83% and 78% for P1 tumors, respectively. Patients with muscle invasive (P2 and P3a), lymph node–negative tumors had 89% and 87% and 78% and 76% 5- and 10-year recurrence-free survival, respectively. Patients with nonorgan-confined (P3b, P4), lymph node–negative tumors demonstrated a significantly higher probability of recurrence compared with those with organ-confined bladder cancers (P < .001). The 5- and 10-year recurrence-free survival for P3b tumors was 62% and 61%, and for P4 tumors was 50% and 45% , respectively. A total of 246 patients (24%) had lymph node tumor involvement. The 5- and 10-year recurrence-free survival for these patients was 35%, and 34%, respectively, which was significantly lower than for patients without lymph node involvement (P < .001). Patients could also be stratified by the number of lymph nodes involved and by the extent of the primary bladder tumor (p stage). Patients with fewer than five positive lymph nodes, and whose p stage was organ-confined had significantly improved survival rates. Bladder cancer recurred in 311 patients (30%) . The median time to recurrence among those patients in whom the cancer recurred was 12 months (range, 0.04 to 11.1 years). In 234 patients (22%) there was a distant recurrence, and in 77 patients (7%) there was a local (pelvic) recurrence.
CONCLUSION: These data from a large group of patients support the aggressive surgical management of invasive bladder cancer. Excellent long-term survival can be achieved with a low incidence of pelvic recurrence.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Shirotake, E. Kikuchi, K. Matsumoto, S. Yazawa, T. Kosaka, A. Miyajima, K. Nakagawa, and M. Oya
Role of Pelvic Lymph Node Dissection in Lymph Node-Negative Patients with Invasive Bladder Cancer
Jpn. J. Clin. Oncol.,
November 3, 2009;
(2009)
hyp147v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Kibel, F. Dehdashti, M. D. Katz, A. P. Klim, R. L. Grubb, P. A. Humphrey, C. Siegel, D. Cao, F. Gao, and B. A. Siegel
Prospective Study of [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Staging of Muscle-Invasive Bladder Carcinoma
J. Clin. Oncol.,
September 10, 2009;
27(26):
4314 - 4320.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Efstathiou, K. Bae, W. U. Shipley, D. S. Kaufman, M. P. Hagan, N. M. Heney, and H. M. Sandler
Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06
J. Clin. Oncol.,
September 1, 2009;
27(25):
4055 - 4061.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Hashine, Y. Kusuhara, N. Miura, A. Shirato, Y. Sumiyoshi, and M. Kataoka
Bladder Preservation Therapy Conducted by Intra-arterial Chemotherapy and Radiotherapy for Muscle Invasive Bladder Cancer
Jpn. J. Clin. Oncol.,
June 1, 2009;
39(6):
381 - 386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W.F. Catto, M. F. Abbod, D. A. Linkens, S. Larre, D. J. Rosario, and F. C. Hamdy
Neurofuzzy Modeling to Determine Recurrence Risk Following Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of the Bladder
Clin. Cancer Res.,
May 1, 2009;
15(9):
3150 - 3155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Bellmunt, S. Albiol, V. Kataja, and On behalf of the ESMO Guidelines Working Group
Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc.,
May 1, 2009;
20(suppl_4):
iv79 - iv80.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. K. Hollenbeck, Z. Ye, R. L. Dunn, J. E. Montie, and J. D. Birkmeyer
Provider Treatment Intensity and Outcomes for Patients With Early-Stage Bladder Cancer
J Natl Cancer Inst,
April 15, 2009;
101(8):
571 - 580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. Shariat, P. I. Karakiewicz, G. Godoy, and S. P. Lerner
Review: Use of nomograms for predictions of outcome in patients with advanced bladder cancer
Therapeutic Advances in Urology,
April 1, 2009;
1(1):
13 - 26.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. Margulis, Y. Lotan, P. I. Karakiewicz, Y. Fradet, R. Ashfaq, U. Capitanio, F. Montorsi, P. J. Bastian, M. E. Nielsen, S. C. Muller, et al.
Multi-Institutional Validation of the Predictive Value of Ki-67 Labeling Index in Patients With Urinary Bladder Cancer
J Natl Cancer Inst,
January 21, 2009;
101(2):
114 - 119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Thurairaja, U. E. Studer, and F. C. Burkhard
Indications, Extent, and Benefits of Pelvic Lymph Node Dissection for Patients with Bladder and Prostate Cancer
Oncologist,
January 1, 2009;
14(1):
40 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Boorjian, Y. Sheinin, P. L. Crispen, S. A. Farmer, C. M. Lohse, S. M. Kuntz, B. C. Leibovich, E. D. Kwon, and I. Frank
T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival
Clin. Cancer Res.,
August 1, 2008;
14(15):
4800 - 4808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ide, E. Kikuchi, A. Miyajima, K. Nakagawa, T. Ohigashi, J. Nakashima, and M. Oya
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
Jpn. J. Clin. Oncol.,
May 1, 2008;
38(5):
360 - 364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Kassouf, P. K. Agarwal, H. W. Herr, M. F. Munsell, P. E. Spiess, G. A. Brown, L. Pisters, H. B. Grossman, C. P. Dinney, and A. M. Kamat
Lymph Node Density Is Superior to TNM Nodal Status in Predicting Disease-Specific Survival After Radical Cystectomy for Bladder Cancer: Analysis of Pooled Data From MDACC and MSKCC
J. Clin. Oncol.,
January 1, 2008;
26(1):
121 - 126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Miyanaga, H. Akaza, S. Hinotsu, A. Joraku, T. Oikawa, N. Sekido, K. Kawai, and T. Shimazui
Background Variables for the Patients with Invasive Bladder Cancer Suitable for Bladder-preserving Therapy
Jpn. J. Clin. Oncol.,
November 1, 2007;
37(11):
852 - 857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Yates, I. Rehman, M. F. Abbod, M. Meuth, S. S. Cross, D. A. Linkens, F. C. Hamdy, and J. W.F. Catto
Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer
Clin. Cancer Res.,
April 1, 2007;
13(7):
2046 - 2053.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Margulis, S. F. Shariat, R. Ashfaq, A. I. Sagalowsky, and Y. Lotan
Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease
Clin. Cancer Res.,
December 15, 2006;
12(24):
7369 - 7373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Parekh, B. H. Bochner, and G. Dalbagni
Superficial and Muscle-Invasive Bladder Cancer: Principles of Management for Outcomes Assessments
J. Clin. Oncol.,
December 10, 2006;
24(35):
5519 - 5527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. Shariat, P. I. Karakiewicz, G. S. Palapattu, G. E. Amiel, Y. Lotan, C. G. Rogers, A. Vazina, P. J. Bastian, A. Gupta, A. I. Sagalowsky, et al.
Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy.
Clin. Cancer Res.,
November 15, 2006;
12(22):
6663 - 6676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kikuchi, Y. Horiguchi, J. Nakashima, T. Ohigashi, M. Oya, K. Nakagawa, A. Miyajima, and M. Murai
Assessment of Long-Term Quality of Life Using the FACT-BL Questionnaire in Patients with an Ileal Conduit, Continent Reservoir, or Orthotopic Neobladder
Jpn. J. Clin. Oncol.,
November 1, 2006;
36(11):
712 - 716.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
International Bladder Cancer Nomogram Consortium
Postoperative Nomogram Predicting Risk of Recurrence After Radical Cystectomy for Bladder Cancer
J. Clin. Oncol.,
August 20, 2006;
24(24):
3967 - 3972.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Sternberg
Are Nomograms Better Than Currently Available Stage Groupings for Bladder Cancer?
J. Clin. Oncol.,
August 20, 2006;
24(24):
3819 - 3820.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Rinker-Schaeffer, J. P. O'Keefe, D. R. Welch, and D. Theodorescu
Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms, and Clinical Application.
Clin. Cancer Res.,
July 1, 2006;
12(13):
3882 - 3889.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Picchio, U. Treiber, A. J. Beer, S. Metz, P. Bossner, H. van Randenborgh, R. Paul, G. Weirich, M. Souvatzoglou, R. Hartung, et al.
Value of 11C-Choline PET and Contrast-Enhanced CT for Staging of Bladder Cancer: Correlation with Histopathologic Findings
J. Nucl. Med.,
June 1, 2006;
47(6):
938 - 944.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Cohen, A. Goel, J. Phillips, R. D. Ennis, and M. L. Grossbard
The Role of Perioperative Chemotherapy in the Treatment of Urothelial Cancer
Oncologist,
June 1, 2006;
11(6):
630 - 640.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Weiss, C. Wolze, D. G. Engehausen, O. J. Ott, F. S. Krause, K.-M. Schrott, J. Dunst, R. Sauer, and C. Rodel
Radiochemotherapy After Transurethral Resection for High-Risk T1 Bladder Cancer: An Alternative to Intravesical Therapy or Early Cystectomy?
J. Clin. Oncol.,
May 20, 2006;
24(15):
2318 - 2324.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Girgin, M. Oder, M. O. Sahin, A. Sezer, S. Berkmen, R. Aydin, and C. Dincel
Erection- and Ejaculation-Preserving Cystectomy With Orthotopic Urinary Diversion: Is It Feasible?
J Androl,
March 1, 2006;
27(2):
263 - 267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Moussa, J. S. Yordy, H. Abol-Enein, D. Sinha, N. K. Bissada, P. V. Halushka, M. A. Ghoneim, and D. K. Watson
Prognostic and Functional Significance of Thromboxane Synthase Gene Overexpression in Invasive Bladder Cancer
Cancer Res.,
December 15, 2005;
65(24):
11581 - 11587.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Lotan, A. Gupta, S. F. Shariat, G. S. Palapattu, A. Vazina, P. I. Karakiewicz, P. J. Bastian, C. G. Rogers, G. Amiel, P. Perotte, et al.
Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy
J. Clin. Oncol.,
September 20, 2005;
23(27):
6533 - 6539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C. Sak, P. Harnden, C. F. Johnston, A. B. Paul, and A. E. Kiltie
APE1 and XRCC1 Protein Expression Levels Predict Cancer-Specific Survival Following Radical Radiotherapy in Bladder Cancer
Clin. Cancer Res.,
September 1, 2005;
11(17):
6205 - 6211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Titus, H. F. Frierson Jr., M. Conaway, K. Ching, T. Guise, J. Chirgwin, G. Hampton, and D. Theodorescu
Endothelin Axis Is a Target of the Lung Metastasis Suppressor Gene RhoGDI2
Cancer Res.,
August 15, 2005;
65(16):
7320 - 7327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Fleischmann, G. N. Thalmann, R. Markwalder, and U. E. Studer
Extracapsular Extension of Pelvic Lymph Node Metastases From Urothelial Carcinoma of the Bladder Is an Independent Prognostic Factor
J. Clin. Oncol.,
April 1, 2005;
23(10):
2358 - 2365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Goebell, S. Groshen, B. J. Schmitz-Drager, R. Sylvester, M. Kogevinas, N. Malats, G. Sauter, H. B. Grossman, C. P.N. Dinney, F. Waldman, et al.
Concepts for Banking Tissue in Urologic Oncology--The International Bladder Cancer Bank
Clin. Cancer Res.,
January 15, 2005;
11(2):
413 - 415.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tekes, I. Kamel, K. Imam, G. Szarf, M. Schoenberg, K. Nasir, R. Thompson, and D. Bluemke
Dynamic MRI of Bladder Cancer: Evaluation of Staging Accuracy
Am. J. Roentgenol.,
January 1, 2005;
184(1):
121 - 127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. M. L. L. G. Deserno, M. G. Harisinghani, M. Taupitz, G. J. Jager, J. A. Witjes, P. F. Mulders, C. A. Hulsbergen van de Kaa, D. Kaufmann, and J. O. Barentsz
Urinary Bladder Cancer: Preoperative Nodal Staging with Ferumoxtran-10-enhanced MR Imaging
Radiology,
November 1, 2004;
233(2):
449 - 456.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Madersbacher, G. N. Thalmann, J. C. Fritsch, and U. E. Studer
Is Eligibility for a Chemotherapy Protocol a Good Prognostic Factor for Invasive Bladder Cancer After Radical Cystectomy?
J. Clin. Oncol.,
October 15, 2004;
22(20):
4103 - 4108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H. Lange and D. W. Lin
Does the Who and How of Surgery in Bladder Cancer Matter?
J. Clin. Oncol.,
July 15, 2004;
22(14):
2762 - 2764.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. W. Herr, J. R. Faulkner, H. B. Grossman, R. B. Natale, R. deVere White, M. F. Sarosdy, and E. D. Crawford
Surgical Factors Influence Bladder Cancer Outcomes: A Cooperative Group Report
J. Clin. Oncol.,
July 15, 2004;
22(14):
2781 - 2789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kent, H. Sandler, J. Montie, C. Lee, J. Herman, P. Esper, J. Fardig, and D. C. Smith
Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial
J. Clin. Oncol.,
July 1, 2004;
22(13):
2540 - 2545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tsukamoto, H. Kitamura, A. Takahashi, and N. Masumori
Treatment of Invasive Bladder Cancer: Lessons from the Past and Perspective for the Future
Jpn. J. Clin. Oncol.,
June 1, 2004;
34(6):
295 - 306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Modlich, H.-B. Prisack, G. Pitschke, U. Ramp, R. Ackermann, H. Bojar, T. A. Vogeli, and M.-O. Grimm
Identifying Superficial, Muscle-Invasive, and Metastasizing Transitional Cell Carcinoma of the Bladder: Use of cDNA Array Analysis of Gene Expression Profiles
Clin. Cancer Res.,
May 15, 2004;
10(10):
3410 - 3421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Kaufman, W. U. Shipley, W. S. McDougal, and R. H. Young
Case 3-2004 - A 57-Year-Old Man with Invasive Transitional-Cell Carcinoma of the Bladder
N. Engl. J. Med.,
January 22, 2004;
350(4):
394 - 402.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Takahashi, T. Tsukamoto, K.-i. Tobisu, N. Shinohara, K. Sato, Y. Tomita, S.-i. Komatsubara, O. Nishizawa, T. Igarashi, H. Fujimoto, et al.
Radical Cystectomy for Invasive Bladder Cancer: Results of Multi-institutional Pooled Analysis
Jpn. J. Clin. Oncol.,
January 1, 2004;
34(1):
14 - 19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ikeda
Non-invasive Management of Invasive Bladder Cancer: Lectures by Professor William U. Shipley
Jpn. J. Clin. Oncol.,
November 1, 2003;
33(11):
592 - 594.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. F. Catto, D. A. Linkens, M. F. Abbod, M. Chen, J. L. Burton, K. M. Feeley, and F. C. Hamdy
Artificial Intelligence in Predicting Bladder Cancer Outcome: A Comparison of Neuro-Fuzzy Modeling and Artificial Neural Networks
Clin. Cancer Res.,
September 15, 2003;
9(11):
4172 - 4177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Madersbacher, W. Hochreiter, F. Burkhard, G. N. Thalmann, H. Danuser, R. Markwalder, and U. E. Studer
Radical Cystectomy for Bladder Cancer Today--A Homogeneous Series Without Neoadjuvant Therapy
J. Clin. Oncol.,
February 15, 2003;
21(4):
690 - 696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rodel, G. G. Grabenbauer, R. Kuhn, T. Papadopoulos, J. Dunst, M. Meyer, K. M. Schrott, and R. Sauer
Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term Results
J. Clin. Oncol.,
July 15, 2002;
20(14):
3061 - 3071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Vogelzang
Neoadjuvant MVAC: The Long and Winding Road Is Getting Shorter and Straighter
J. Clin. Oncol.,
October 15, 2001;
19(20):
4003 - 4004.
[Full Text]
[PDF]
|
|
|
|
